Pycnogenol attenuates atherosclerosis by regulating lipid metabolism through the TLR4-NF-κB pathway

Experimental and Molecular Medicine

Volumn 47, Issue 10, 2015, Pages

  Luo, Hong ^a   Wang, Jing ^a   Qiao, Chenhui ^a   Ma, Ning ^a   Liu, Donghai ^a   Zhang, Weihua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTE LIPID BINDING PROTEIN; ADIPOPHILIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID BINDING PROTEIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYCNOGENOL; PYRROLIDINE DITHIOCARBAMATE; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; FLAVONOID; PYCNOGENOLS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIATHEROSCLEROTIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; LIPID METABOLISM; LIPID STORAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CELL LINE; DRUG EFFECTS; FOAM CELL; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CELL LINE; FLAVONOIDS; FOAM CELLS; HUMANS; LIPID METABOLISM; MALE; MICE; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84955719055     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2015.74     Document Type: Article

References (31)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
2. Hansson GK, Robertson A-KL, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis 2006; 1: 297-329.
3. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr 2012; 95: 454-464.
4. Mulvihill EE, Huff MW. Protection from metabolic dysregulation, obesity, and atherosclerosis by citrus flavonoids: activation of hepatic PGC1α-mediated fatty acid oxidation. PPAR Res 2012; 2012: 857142.
5. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutr Res 2008; 28: 315-320.
6. Watson R. Reduction of cardiovascular disease risk factors by French maritime pine bark extract. Cardiovasc Rev Rep 1999; 20: 326-329.
7. Yamamoto K, Ando J. New molecular mechanisms for cardiovascular disease:blood flow sensing mechanism in vascular endothelial cells. J Pharmacol Sci 2011; 116: 323-331.
8. Favero G, Paganelli C, Buffoli B, Rodella LF, Rezzani R. Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int 2014; 2014: 801896.
9. Mehta JL, Basnakian AG. Interaction of carbamylated LDL with LOX-1 in the induction of endothelial dysfunction and atherosclerosis. Eur Heart J 2014; 35: 2996-2997.
10. Enseleit F, Sudano I, Périat D, Winnik S, Wolfrum M, Flammer AJ et al. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J 2012; 33: 1589-1597.
11. Feng X. Natural IgM specific for oxLDL protects murine macrophages from foam cells formation but lipopolysaccharide (LPS) disrupts the course by up-regulating the expression of Fcα/μ receptor. Heart 2011; 97: A58-A58.
12. Cai Y, Li J-D, Yan C. Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochem Biophys Res Commun 2013; 434: 439-443.
13. Chapman KD, Dyer JM, Mullen RT. Biogenesis and functions of lipid droplets in plants: Thematic Review Series: Lipid Droplet Synthesis and Metabolism: from Yeast to Man. J Lipid Res 2012; 53: 215-226.
14. Imamura M, Inoguchi T, Ikuyama S, Taniguchi S, Kobayashi K, Nakashima N et al. ADRP stimulates lipid accumulation and lipid droplet formation in murine fibroblasts. Am J Physiol Endocrinol Metab 2002; 283: E775-E783.
15. Paul A, Chang BH-J LiL, Yechoor VK, Chan L. Deficiency of adipose differentiation-related protein impairs foam cell formation and protects against atherosclerosis. Circ Res 2008; 102: 1492-1501.
16. Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol 2005; 25: 1220-1224.
17. Fu Y, Luo N, Lopes-Virella MF, Garvey WT. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 2002; 165: 259-269.
18. Gu J-Q, Ikuyama S, Wei P, Fan B, Oyama J-i, Inoguchi T et al. Pycnogenol, an extract from French maritime pine, suppresses Toll-like receptor 4-mediated expression of adipose differentiation-related protein in macrophages. Am J Physiol Endocrinol Metab 2008; 295: E1390-E1400.
19. Li R, Chen B, Wu W, Bao L, Li J, Qi R. Ginkgolide B suppresses intercellular adhesion molecule-1 expression via blocking nuclear factorκb activation in human vascular endothelial cells stimulated by oxidized low-density lipoprotein. J Pharmacol Sci 2009; 110: 362-369.
20. den Dekker WK, Cheng C, Pasterkamp G. Duckers HJ. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010; 209: 314-320.
21. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R et al. Endothelial cell-specific NF-κB inhibition protects mice from atherosclerosis. Cell Metab 2008; 8: 372-383.
22. Pankow JS, Boerwinkle E, Adams PC, Guallar E, Leiendecker-Foster C, Rogowski J et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res 2008; 152: 3-10.
23. Sparks LM, Moro C, Ukropcova B, Bajpeyi S, Civitarese AE, Hulver MW et al. Remodeling lipid metabolism and improving insulin responsiveness in human primary myotubes. PLoS ONE 2011; 6: e21068.
24. Fu Y, Luo L, Luo N, Garvey WT. Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis 2006; 188: 102-111.
25. Lu Z, Zhang X, Li Y, Jin J, Huang Y. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice. J Endocrinol 2013; 216: 61-71.
26. Michelsen KS, Doherty TM, Shah PK, Arditi M. Role of Toll-like receptors in atherosclerosis. Circulation Res 2004; 95: e96-e97.
27. Kim S, Park J, Kim K, Lee W, Kim K, Park K. Melittin inhibits atherosclerosis in LPS/high-fat treated mice through atheroprotective actions. J Atheroscler Thromb 2011; 18: 1117-1126.
28. Feingold KR, Kazemi MR, Magra AL, McDonald CM, Chui LG, Shigenaga JK et al. ADRP/ADFP and Mal1 expression are increased in macrophages treated with TLR agonists. Atherosclerosis 2010; 209: 81-88.
29. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-10684.
30. Muhlestein JB. Bacterial infections and atherosclerosis. J Investig Med 1998; 46: 396-402.
31. Lee MS, Moon KY, Bae DJ, Park MK, Jang AS. The effects of pycnogenol on antioxidant enzymes in a mouse model of ozone exposure. Korean J Intern Med 2013; 28: 216-223.